AGLE News and Press, Aeglea BioTherapeutics Inc. From 07/08/21

Aeglea BioTherapeutics Appoints Jonathan D. Alspaugh as Chief Financial Officer PR Newswire AUSTIN, Texas , July 8, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human ...

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

Aeglea BioTherapeutics (AGLE) announces the dosing of the first patient in the company's first-in-human Phase 1/2 clinical trial investigating AGLE-177 for the treatment of Homocystinuria, an rare inherited disorder of methionine metabolism.AGLE-177 is a novel engineered human enzyme the...

Aeglea BioTherapeutics Doses First Patient in a Phase 1/2 Clinical Trial of AGLE-177, a Potential First-in-Class Treatment for Homocystinuria PR Newswire AUSTIN, Texas , June 24, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage b...

Aeglea BioTherapeutics Appoints Marcio Souza to Board of Directors PR Newswire AUSTIN, Texas , June 22, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeuti...

Gainers: [[RPHM]] +11.9%. [[BLI]] +6%. [[ARVN]] +5.6%. [[BKEPP]] +3.9%. [[LAKE]] +3.1%.Losers: [[OLED]] -7.2%. [[LMNL]] -5.2%. [[PXLW]] -3.7%. [[FUTU]] -3%. [[AGLE]] -2.3%. For further details see: OLED, FUTU, LAKE and BLI among after-hours movers

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company developing enzyme therapeutics for rare metabolic diseases with limited treatment options. Aeglea's pipeline consists of two clinical-stage therapeutics and one in the late-pre-clinical stage covering primarily met...

Aeglea BioTherapeutics (AGLE): Q1 GAAP EPS of -$0.28 misses by $0.14.Cash, cash equivalents, marketable securities and restricted cash of $128.5M. Based on Aeglea's current operating plan, management believes it has sufficient capital resources to fund anticipated operations into 2023.Press R...

Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights Completed Patient Randomization for Phase 3 PEACE Clinical Trial; Topline Data Expected in Q4 Entered into Ex-U.S. Commercialization Agreement for Pegzilarginase with Upfront and Mil...

Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency Includes Sponsored Diagnostic Testing and Services for Patients with Suspected Arginase 1 Deficiency PR Newswire A...